Chronic central Interleukin-6 overexpression drives hippocampal and cortical neuropathology in Tg2576 Alzheimer's mice
Background
Interleukin-6 (IL-6) is a cytokine implicated in Alzheimer's disease (AD), with elevated levels observed in both patients and mouse models, correlating with amyloid-beta (Aβ) burden. While IL-6 deficiency has shown cognitive benefits and reduced hippocampal neuroinflammation, astrocyte-targeted IL-6 signaling via its soluble receptor can worsen pathological features. This dual role highlights a critical gap: the precise overall impact of chronic central IL-6 overexpression on AD pathophysiology, considering its ability to signal through both classical membrane-bound and soluble receptor pathways, remains incompletely understood.
Study Design
Researchers investigated the impact of chronic central IL-6 overexpression by crossing Tg2576 mice, a model of Aβ-driven amyloidosis, with GFAP-IL6 mice, which express IL-6 predominantly in astrocytes. The study assessed AD-related mortality, metabolic changes (e.g., adiposity, body weight), behavioral alterations, and neuroinflammatory markers in the hippocampus and cortex. They analyzed Aβ42/Aβ40 ratios, gliosis, and the distribution/reactivity of astrocytes and microglia in aged male and female Tg2576 mice with and without central IL-6 overexpression.
Results
Chronic central IL-6 overexpression significantly impacted Tg2576 mice. Metabolic effects included reduced inguinal white adiposity in both males and females, and decreased body weight specifically in females. Early behavioral alterations were observed, with IL-6 overexpression regulating behavior in an age- and sex-dependent manner. Crucially, aged female and male Tg2576 mice with central IL-6 overexpression exhibited increased cortical and hippocampal Aβ42/Aβ40 ratios, a key indicator of amyloid pathology. This was accompanied by widespread gliosis, indicating neuroinflammation. Interestingly, the spatial distribution of gliosis was nuanced: > Chronic central-targeted IL-6 overexpression increased overall gliosis in the cortical and hippocampal parenchyma but reduced gliosis in the immediate vicinity of cortical and hippocampal amyloid plaques. This suggests a complex, context-dependent role for IL-6 in modulating glial responses around Aβ deposits.
Key Findings
- Central
IL-6overexpression increased cortical and hippocampalAβ42/Aβ40ratios in aged Tg2576 mice. - Chronic central
IL-6overexpression induced overall gliosis in cortical and hippocampal parenchyma. - IL-6 overexpression reduced gliosis in the vicinity of cortical and hippocampal amyloid plaques.
- Reduced inguinal white adiposity was observed in both sexes, and decreased body weight in females.
- Early behavioral alterations were regulated in an age- and sex-dependent manner by
IL-6overexpression.
Why It Matters
This study underscores IL-6 as a critical modulator of Alzheimer's disease pathology, suggesting that chronic central IL-6 overexpression actively contributes to neurodegeneration and Aβ accumulation. Modulating central IL-6 activity could represent a novel therapeutic strategy for AD, potentially by targeting specific IL-6 signaling pathways or cell types like astrocytes. While this is a preclinical animal study, it provides mechanistic insights into how neuroinflammation, driven by specific cytokines, can directly influence Aβ processing and glial responses. Further research is needed to translate these findings into human-relevant protocols, but it highlights the importance of considering inflammatory pathways in AD interventions beyond direct Aβ clearance.
alzheimers
neuroinflammation
interleukin-6
amyloid-beta
gliosis
preclinical-animal